Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline WAZ, fecal AAT concentration, and plasma concentrations of FGF21, ferritin, retinol, vitamin D, zinc, and CRP were nonnormally distributed based on significant Shapiro: Wilk tests.

Source: Plasma FGF21 distribution, categorization, and cofactors. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Plasma Fibroblast Growth Factor 21 Is Associated with Subsequent Growth in a Cohort of Underweight Children in Bangladesh

Review / evidence synthesis · Current Developments in Nutrition · 2019

Original publication title

Plasma Fibroblast Growth Factor 21 Is Associated with Subsequent Growth in a Cohort of Underweight Children in Bangladesh

Michael B Arndt; Barbra A Richardson; Mustafa Mahfuz; Tahmeed Ahmed; Rashidul Haque; Md Amran Gazi; Grace C John-Stewart; Donna M Denno; Jarrad M Scarlett; Judd L Walson; coordination with The Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development Project Network

Copyright © American Society for Nutrition 2019.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

FGF21 may be a useful marker of growth faltering and may allow identification of children who are more or less likely to respond to nutritional supplementation. This trial was registered at clinicaltrials.gov as NCT02441426.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

We aimed to determine the associations between plasma FGF21 concentrations and subsequent growth, and the association between change in FGF21 concentrations and concurrent growth, in children receiving nutritional supplementation.

Source: Objectives

Abstract: What methods does the paper describe?

A total of 120 children between ages 6 and 13 mo with weight-for-age z score (WAZ) between −3 and −2 were enrolled from an urban slum in Dhaka, Bangladesh. Children received 376-kcal feeding supplements daily for 5 mo and were followed for 5 additional mo. FGF21 was measured in plasma collected at enrollment and month 5. FGF21 values that fell above the 90th percentile of baseline concentrations (1056.5 pg/mL) were considered high. Linear regression was used to examine the association between baseline FGF21 status and 5-mo change in WAZ and length-for-age z score (LAZ), and the association between 5-mo change in FGF21 and concurrent WAZ and LAZ change.

Source: Methods

Abstract: Results

The median baseline FGF21 concentration was 241.4 pg/mL (IQR: 111.7, 451.3 pg/mL). On average, children with high baseline FGF21 gained 0.58 WAZ (95% CI: 0.28, 0.88) and 0.54 LAZ (95% CI: 0.23, 0.84) more during supplementation than those with low values. Change in FGF21 concentration during supplementation was negatively associated with change in WAZ (−0.48; 95% CI: −0.67, −0.29) and LAZ (−0.31; 95% CI: −0.52, −0.11).

Source: Results

Abstract: Conclusions

FGF21 may be a useful marker of growth faltering and may allow identification of children who are more or less likely to respond to nutritional supplementation. This trial was registered at clinicaltrials.gov as NCT02441426.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Current nutritional intervention strategies have not proven effective in improving childhood ponderal and linear growth in underweight and stunted children. Novel markers are needed to classify children who are likely to respond to available interventions and to identify those requiring additional interventions. Fibroblast Growth Factor 21 (FGF21), an endocrine hormone that regulates metabolism and growth during periods of reduced protein intake, may be useful in this context.

Objectives

We aimed to determine the associations between plasma FGF21 concentrations and subsequent growth, and the association between change in FGF21 concentrations and concurrent growth, in children receiving nutritional supplementation.

Methods

A total of 120 children between ages 6 and 13 mo with weight-for-age z score (WAZ) between −3 and −2 were enrolled from an urban slum in Dhaka, Bangladesh. Children received 376-kcal feeding supplements daily for 5 mo and were followed for 5 additional mo. FGF21 was measured in plasma collected at enrollment and month 5. FGF21 values that fell above the 90th percentile of baseline concentrations (1056.5 pg/mL) were considered high. Linear regression was used to examine the association between baseline FGF21 status and 5-mo change in WAZ and length-for-age z score (LAZ), and the association between 5-mo change in FGF21 and concurrent WAZ and LAZ change.

Results

The median baseline FGF21 concentration was 241.4 pg/mL (IQR: 111.7, 451.3 pg/mL). On average, children with high baseline FGF21 gained 0.58 WAZ (95% CI: 0.28, 0.88) and 0.54 LAZ (95% CI: 0.23, 0.84) more during supplementation than those with low values. Change in FGF21 concentration during supplementation was negatively associated with change in WAZ (−0.48; 95% CI: −0.67, −0.29) and LAZ (−0.31; 95% CI: −0.52, −0.11).

Conclusions

FGF21 may be a useful marker of growth faltering and may allow identification of children who are more or less likely to respond to nutritional supplementation. This trial was registered at clinicaltrials.gov as NCT02441426.

Publication and source details

Original title: Plasma Fibroblast Growth Factor 21 Is Associated with Subsequent Growth in a Cohort of Underweight Children in Bangladesh

Michael B Arndt; Barbra A Richardson; Mustafa Mahfuz; Tahmeed Ahmed; Rashidul Haque; Md Amran Gazi; Grace C John-Stewart; Donna M Denno; Jarrad M Scarlett; Judd L Walson; coordination with The Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development Project Network

Current Developments in Nutrition · 2019

Address correspondence to MBA (e-mail: marndt@uw.edu)Copyright © American Society for Nutrition 2019.2019https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:41:12.117457+00:00

DOI: 10.1093/cdn/nzz024 · PMC6511337